Terry  Dagnon net worth and biography

Terry Dagnon Biography and Net Worth

Mr. Dagnon has served as our Chief Operating Officer since November 2018. He was most recently Senior Vice President of Operations at Dohmen Life Science Services. Terry’s 20 years of regulatory experience has involved responsibility from research to post-market with a large number of domestic and global investigational and marketing approvals in the pharmaceutical and medical device industries. He is also experienced in quality and compliance and working with R&D, Marketing, Sales, Legal, and Manufacturing, Quality and Supply Chain organizations. Terry began his career in the pharmaceutical industry as the Regulatory Affairs Manager for Physician Reliance Network Inc. (now known as U.S. Oncology). He continued his regulatory affairs career at Johnson & Johnson Medical Inc. with global regulatory responsibility for the Wound Care, Skin Care and Tissue Engineering franchises. He then served as the North America Head of Regulatory Affairs at Alcon a Novartis company prior to joining DLSS in March 2014. At Dohmen Life Science Services he was responsible for all operational activities at the Denver site and in running the following service lines servicing Pharmaceutical, Biologics, MedTech, and Rare industry segments: QA/RA/Safety/Medical Affairs/CMC/Project Management Consulting and Quality Management System Outsourcing.

What is Terry Dagnon's net worth?

The estimated net worth of Terry Dagnon is at least $268,072.92 as of April 20th, 2023. Mr. Dagnon owns 32,652 shares of Outlook Therapeutics stock worth more than $268,073 as of May 7th. This net worth approximation does not reflect any other assets that Mr. Dagnon may own. Learn More about Terry Dagnon's net worth.

How do I contact Terry Dagnon?

The corporate mailing address for Mr. Dagnon and other Outlook Therapeutics executives is 4260 U.S. ROUTE 1, MONMOUTH JUNCTION NJ, 08852. Outlook Therapeutics can also be reached via phone at (609) 619-3990 and via email at [email protected]. Learn More on Terry Dagnon's contact information.

Has Terry Dagnon been buying or selling shares of Outlook Therapeutics?

Terry Dagnon has not been actively trading shares of Outlook Therapeutics during the past quarter. Most recently, Terry Dagnon sold 26,000 shares of the business's stock in a transaction on Thursday, April 20th. The shares were sold at an average price of $22.80, for a transaction totalling $592,800.00. Following the completion of the sale, the insider now directly owns 32,652 shares of the company's stock, valued at $744,465.60. Learn More on Terry Dagnon's trading history.

Who are Outlook Therapeutics' active insiders?

Outlook Therapeutics' insider roster includes Terry Dagnon (COO), Jeff Evanson (Insider), Yezan Haddadin (Director), Ghiath Sukhtian (Director), and C Trenary, III (CEO). Learn More on Outlook Therapeutics' active insiders.

Are insiders buying or selling shares of Outlook Therapeutics?

In the last year, Outlook Therapeutics insiders bought shares 1 times. They purchased a total of 1,882 shares worth more than $22,245.24. The most recent insider tranaction occured on March, 28th when Director Yezan Munther Haddadin bought 1,882 shares worth more than $22,245.24. Insiders at Outlook Therapeutics own 5.3% of the company. Learn More about insider trades at Outlook Therapeutics.

Information on this page was last updated on 3/28/2024.

Terry Dagnon Insider Trading History at Outlook Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/20/2023Sell26,000$22.80$592,800.0032,652View SEC Filing Icon  
6/21/2022Buy500$21.00$10,500.0058,652View SEC Filing Icon  
12/6/2021Buy1,260$27.60$34,776.00View SEC Filing Icon  
2/23/2021Sell795$41.80$33,231.0056,392View SEC Filing Icon  
2/12/2021Sell3,185$51.00$162,435.0057,187View SEC Filing Icon  
See Full Table

Terry Dagnon Buying and Selling Activity at Outlook Therapeutics

This chart shows Terry Dagnon's buying and selling at Outlook Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Outlook Therapeutics Company Overview

Outlook Therapeutics logo
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Read More

Today's Range

Now: $8.21
Low: $8.17
High: $8.76

50 Day Range

MA: $8.53
Low: $5.73
High: $11.94

2 Week Range

Now: $8.21
Low: $4.00
High: $40.60

Volume

200,299 shs

Average Volume

498,598 shs

Market Capitalization

$106.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.28